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Abstract
The gold standard for curative treatment of locally 
advanced rectal cancer involves radical resection 
with a total mesorectal excision (TME). TME is the 
most effective treatment strategy to reduce local 
recurrence and improve survival outcomes regardless 
of the surgical platform used. However, there are 
associated morbidities, functional consequences, and 
quality of life (QoL) issues associated with TME; these 
risks must be considered during the modern-day 
multidisciplinary treatment for rectal cancer. This has 
led to the development of new surgical techniques to 
improve patient, oncologic, and QoL outcomes. In this 
work, we review the evolution of TME to the transanal 
total mesorectal excision (TaTME) through more 
traditional minimally invasive platforms. The review the 
development, safety and feasibility, proposed benefits 
and risks of the procedure, implementation and edu-
cation models, and future direction for research and 
implementation of the TaTME in colorectal surgery. While 
satisfactory short-term results have been reported, the 
procedure is in its infancy, and long term outcomes 
and definitive results from controlled trials are pending. 
As evidence for safety and feasibility accumulates, 
structured training programs to standardize teaching, 
training, and safe expansion will aid the safe spread of 
the TaTME.
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Core tip: The evaluation and management of rectal 
cancer have evolved remarkably over the last few 
decades. Total mesorectal excision (TME) has been 
recognized as the standard surgical management 
for curative radical treatment of rectal cancer. While 
abdominal procedures, whether by the open or mini-
mally invasive approaches, apply the classical concept 
of “top-to-bottom” dissection, the transanal TME 
(TaTME) uses the opposite approach of “bottom-to-
top” dissection. In this review we discuss the evolution 
of TME for rectal cancer to the TaTME, its technical 
aspects, advantages, shortcomings, and current needs. 
The research and education initiatives as well as future 
directions of TaTME were also highlighted.
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Gastrointest Surg 2018; 10(3): 28-39  Available from: URL: 
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INTRODUCTION
Despite the current multidisciplinary modern mana­
gement, rectal cancer remains a formidable challenge 
for the colorectal surgeon. Surgical therapy for rectal 
cancer has evolved since Dr. Ernest Miles described the 
abdominoperineal resection in 1908. With this radical 
resection and the realization that rectal cancer must be 
tackled from the both abdomen and perineum, Miles 
reduced the local recurrence rate from nearly 100% 
to 30%[1]. Defining the “zone of upward spread” he 
introduced the concept of surgical oncology whereby 
the tumor, blood supply and nodal tissue needed to be 
excised.
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With better surgical tools enabling a low anastomosis, 
a shift toward sphincter­saving approaches began, 
with the anterior resection replacing abdominoperineal 
resection as the standard curative resection, when 
possible. These approaches resulted in poor oncologic 
outcomes for recurrence and overall survival. Technical 
advancement came to light in 1982, when Heald et al[2] 
published the total mesorectal excision (TME) technique. 
The TME entails sharp, nerve­sparing dissection in 
the avascular plane between the mesorectum and 
surrounding structures circumferentially. A complete 
TME with intact fascia and no invasion into the muscular 
coat or mucosa is an important, positive prognosticator 
against locoregional tumor recurrence[3]. 
TME became the gold standard for curative resection 
from proven better local control and survival[4]. Neoad­
juvant and adjuvant chemotherapy and radiotherapy 
serve as adjuvants to improve the outcome after surgery; 
the dose and timing of these adjuncts are variable based 
on the disease stage and patient­related factors[5­14]. 
However, these adjuncts are not a substitute for a proper 
TME, with poor surgery yielding an inadequate surgical 
specimen invariably leading to local recurrence[15]. 
Additional evidence from the Medical Research Council 
of United Kingdom CR07 and National Cancer Institute 
of Canada­CTG CO16 (CR07) trial highlighted the 
importance of good quality surgery, and how inadequate 
surgery can be only minimally compensated for by 
chemoradiotherapy[3,16]. In the early 1990’s, laparoscopic 
surgery was introduced, and gradually become applied to 
colon and rectal cancer. While there were initial concerns 
about the oncological safety of laparoscopy, the Clinical 
Outcomes of Surgical Therapy (COST) Trial demonstrated 
the safety, oncologic equivalency, and clinical benefits 
over open surgery[17]. Abundant support has reported 
comparable oncologic outcomes and improves short­
term benefits of laparoscopic over open surgery for rectal 
cancer[3,18­21]. The safety of laparoscopy for rectal cancer 
was less clearly defined initially, as early controlled trials 
concentrated on the oncologic safety of colon cancer[17,20]. 
While skepticism remained, the improved outcomes 
with TME were shown to be generalizable in both open 
and minimally invasive approaches[3,6,22­28]. Then recent 
studies further questioned the oncologic equivalence of 
the laparoscopic approach for rectal cancer. The ALaCaRT 
and ACOSOG Z6051 trials failed to establish the non­
inferiority of laparoscopy compared to open rectal cancer 
surgery[29,30]. The authors of ALaCaRT recommended 
using a different platform in low rectal cancers than 
pure abdominal laparoscopy, as working in the deep 
pelvis with rigid, straight laparoscopic instruments 
from difficult angles was challenging and required 
complex maneuvers[29]. Technical limitations exist with 
the laparoscopic approach, especially during the distal 
transection of the rectum, due to limited visualization and 
restriction working in the confined, bony pelvis[31]. These 
limitations highlighted the need for other approaches to 
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rectal cancer. Robotic assisted surgery was introduced 
to address the limitations of laparoscopy, and gained 
acceptance from the improved visualization, lower 
conversion rates, better TME quality lower positive CRM 
rate, and earlier recovery of genitourinary functions[32­34]. 
Studies reported equivalent oncologic and functional 
outcomes of both approaches, which raise the issue 
about the cost­effectiveness of the robotic platform, 
and the need for more effective and cost­efficient 
platforms[35­37]. 
Literature search
For this review, three of the authors reviewed published 
data regarding rectal cancer surgery, with attention to 
surgical techniques over the last several decades leading 
to the transanal TME. With the defined focus, PubMed 
and MEDLINE databases and the #colorectal research 
hashtag on Twitter were searched from database 
inception through September 15, 2017 for articles and 
data published with relevant evidence regarding the 
evolution of surgery for rectal cancer. The following 
search terms were used: “total mesorectal excision”, 
“transanal excision”, “local excision”, “laparoscopic 
colorectal surgery”, and “transanal total mesorectal 
excision”, “TaTME”, “rectal carcinoma” and “rectal 
cancer”. Reference lists were manually searched and 
relevant articles were added if pertinent to the scope 
of the study. Articles were included if in English and the 
full content was available. Conference proceedings and 
videos were not included. 
Evolution of surgical approaches in rectal cancer 
towards the TaTME 
Despite significant advances in technology and use of 
minimally invasive approaches in many other surgical 
disciplines, open surgery remains the gold standard for 
rectal cancer. Technical challenges and subsequent low 
uptake of laparoscopy in low rectal cancer surgery and 
contention on the value of robotic platforms have left 
the door open for a new approach. An ideal approach 
would involve a short learning curve, low relative cost, 
reproducibility and clear evidence of patient safety.
Local excision 
To leverage the benefits of a minimally invasive app­
roach, intraluminal, endoscopic, transanal, and hybrid 
techniques have been expanded in recent years. 
Additional desire to improve not only oncological out­
comes but also function and quality of life outcomes 
led to investigation of local excision techniques[38,39]. 
While local excision has improved functional outcomes 
compared with radical resection, the lack of lymph­
adenectomy and higher rates of positive resection 
margins, locoregional recurrence, and lower overall 
survival means that it may not be directly comparable 
to TME in terms of oncological outcomes[38­45]. Therefore, 
it is currently recommended for benign and early (T1) 
rectal lesions, unless on clinical trial[46,47]. With these 
outcomes, it was necessary to develop more precise 
methods for local excision[48]. 
Transanal endoscopic surgery
Advanced endoscopic platforms, combining the tran­
sanal and minimally invasive approaches addressed the 
limitations of conventional transanal resections, and 
allowed precise dissection of low and mid rectal tumors, 
a limitation of other platforms to date.
Transanal endoscopic microsurgery
In 1983, Dr. Gerhard Buess developed Transanal 
Endoscopic Microsurgery (TEM), (Figure 1), offering 
improved visualization from a stereoscopic magnified 
view in the gas­dilated rectum for precise excision in 
an operative space that would be otherwise difficult to 
reach, as well as significantly lower morbidity, lower 
local recurrence rates, with a higher rate of negative 
resection margins than traditional TAE[49­52]. Widespread 
adoption was limited due to the cost of the specialized 
instrumentation, additional learning curve, and limited 
indications for the technique[53­56].
Transanal minimally invasive surgery
Dr. Sam Atallah introduced Transanal Minimally Invasive 
Surgery (TAMIS), (Figure 2) as an alternate advanced 
videoscopic transanal platform that also combines 
minimally invasive benefits with transanal resection, 
but addresses some limitations of TEM[55]. The same 
superior visualization and reach of TEM is offered but 
using standard laparoscopic equipment reduces the cost 
and learning curve[55,57,58]. The TAMIS platform may also 
be less traumatic to the anal sphincter than TEM[57]. 
A recent systematic review described low conversion 
rate of 2.3%, and low rates of positive margins, tumor 
fragmentation, and overall complications of 4.36%, 
4.1% and 7.4%, respectively[54]. Both TEM and TAMIS 
have limitations in patient selection, lack of adequate 
lymphadenectomy inability to adequately stage the 
pelvis, and prohibitively high recurrence rates with 
Figure 1  Transanal endoscopic microsurgeryplatform.
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T2 and more advanced rectal tumors[55,59­62]. TEM and 
TAMIS remain important in the evolution of the TaTME 
platform.
Natural orifice transluminal endoscopic surgery
Natural orifice transluminal endoscopic surgery (NOTES) 
further pushed the boundaries of minimally invasive 
surgery, eliminating the extraction wound, associated 
pain, risk of wound infection and incisional hernia. The 
per­oral transgastric approach was first developed in 
animal models, and then intensely explored across 
transoral, transanal, transurethral, and transvaginal 
routes, before being cautiously tested in clinical 
practice[63,64]. Dr. Mark Whiteford reported a successful 
NOTES transanal sigmoid colectomy cadaver series 
in 2007[65], while Dr. Patricia Sylla combined the 
transgastric endoscopic and TEM platform in a swine 
rectosigmoid resection series[66]. 
Dr. Antonio Lacy was instrumental in moving the 
concept of NOTES out of the “lab” and into potential 
practise, reporting a sigmoid resection using transvaginal 
mini­laparoscopic­assisted natural orifice surgery for 
sigmoid adenocarcinoma[67]. Using the TEM platform 
in a human rectal cancer series, there seemed to now 
be a safe alternative to open and laparoscopic TME[68]. 
Several colorectal series followed, affirming the feasibility 
of NOTES[69­76]. However for the majority NOTES remains 
experimental, with concerns over the operative platform, 
accidental organ injury and viscerotomy closure[64,73]. 
The potential of performing complex colorectal dissection 
using existing transanal endoscopic platforms fueled the 
movement towards the TaTME.
Trans abdominal trans anal proctosigmoidectomy
Hybrid approaches to rectal cancer were occurring 
long before NOTES. For sphincter preservation and 
conservation of adequate function in very distal lesions, 
Dr. Gerald Marks developed the TransAnal Abdo­
minal TransAnal Proctosigmoidectomy with colo-anal 
anastomosis (TATA) technique in 1984, a transanally 
initiated TME dissection that offers a direct, precise 
distal dissection, assuring adequate distal margins[77,78]. 
Dr. John Marks routinely integrated laparoscopic and 
robotic approaches with TATA, adding the advantages 
of minimally invasive surgery to this groundbreaking 
procedure. The TATA introduced the concept of “bottom­
up” technique, in contrast to the “top­down” traditional 
technique followed in the abdominal procedures. 
Transanal TME
TaTME extends the TATA’s principle of initiating the TME 
dissection transanally (bottom­up) and accomplishes 
the most difficult part of the dissection from the 
caudal side[77]. Sylla and Lacy first described the 
TaTME in 2010[79] followed by an early case series of 
20 patients[68], and a further validated series in 140 
patients[80]. Since these early reports, numerous series 
have described the safety and feasibility of taTME even 
in challenging patients. The theoretical advantages 
of access and visualization have established this 
technique as not only a credible alternative to more 
traditional approaches which has the potential to provide 
optimal outcomes for oncologic resection of low rectal 
cancers[81­91]. 
Indications for TaTME: TaTME is mainly indicated for 
treatment of malignant tumors affecting the middle and 
lower third of the rectum. Moreover, it can be applied in 
benign conditions affecting the rectum such as Crohn’s 
disease and ulcerative colitis. Benign indications for 
TaTME may include reversal of Hartmann’s procedure, 
restorative proctocolectomy or completion proctectomy 
and ileal­pouch anal anastomosis[92].
Technical points of the TaTME: Briefly, the proce­
dure is performed in the modified lithotomy (Lloyd­
Davies) position. It can be performed by a single 
team or, as originally described by Lacy, two­team 
(“Cecil Approach”), which allows for shorter operative 
times, improved visualization, and better traction and 
counter­traction to facilitate the resection (Figure 3). 
The abdominal approach is determined by surgeon 
preference, and entails full left colon and splenic flexure 
mobilization, high ligation of the inferior mesenteric 
artery (with identification and preservation of the pelvic 
nerve plexuses), and division of the inferior mesenteric 
vein was divided at the inferior pancreas border, and a 
TME performed. 
For TaTME, the rectum is irrigated, a purse­string 
suture placed to occlude the rectum, then the Transanal 
Access Platform inserted as shown in Figure 4, and 
pneumorectum established. Performing a tight purse-
string suture is imperative to prevent translocation 
of liquid stool and cancer cells while the dissection is 
being carried out. Adequate rectal irrigation and the 
purse­string suture may help reduce the potential 
for implantation of cancer cells and/or bacteria 
inherent in the transanal dissection plane that could 
result in abscesses or local recurrence. While long­
term outcomes will need to be assessed for these 
risks, measures to prevent the risk include standard 
manipulations and appropriate case selection as well 
as rectal irrigation with a cytocidal solution[93]. Under 
endoscopic visualization, the rectum is circumferentially 
Figure 2  Transanal minimally invasive surgery platform. Photo courtesy of 
Antonio Lacy, Hospital Clinic and AIS Channel.
Emile SH et al . TaTME history
32 March 27, 2018|Volume 10|Issue 3|WJGS|www.wjgnet.com
mobilized, and the dissection continued proximally 
in the avascular TME plane towards the peritoneal 
reflection to meet the abdominal mobilization (Figure 
5)[82,92]. The extraction can be performed transanally, or 
though a Pfannenstiel or stoma-site incision, depending 
on the abdominal approach used and the bulk of the 
specimen.
Safe implementation of TaTME: TaTME may 
enhance distal rectal access and visualization, allowing 
optimal margins, adequate lymph node yield, and 
high quality resection, even in the most difficult 
patients[94­96]. Denost et al[97] showed that the perineal 
approach reduces the risk of positive CRM compared to 
an abdominal approach, and may be an oncologically 
superior approach for low rectal cancer. Report from the 
International TaTME Registry suggests the procedure is 
oncologically safe and effective[83]. Since TaTME is in its 
infancy, longer follow­up and controlled trials needed. 
It is important to note that the TaTME is technically 
challenging, and formal training through a hands­
on course is recommended, with active proctoring 
during the first year and ongoing participation within 
multicenter registries, for quality improvement and 
long term follow up[98]. Consensus for standardization 
of the technique and structured training are ongoing, to 
facilitate safe, appropriate implementation into clinical 
practice[92,98­101].
Advantages of TaTME: In general, transanal app­
roaches allow better visualization of the distal rectum 
and clearly demonstrates the distal resection margin. 
The TaTME furthers these benefits, uniquely allowing 
deep pelvic dissection without the need for traction on 
the rectum. The plane of resection is clearly identified, 
even in obese and male patients with narrow pelvis, 
which were considered unfavorable conditions for 
laparoscopic TME[102].
Oncological benefits: The major potential benefit 
of TaTME is its theoretical ability to obtain a higher 
quality TME specimen. Results from the international 
TaTME registry showed complete or almost complete 
mesorectal excision rate of 96%, CRM positive rate of 
2.4% and DRM positive rate of 0.3%[83]. Similarly, Xu 
et al[103] and colleagues concluded that TaTME provided 
lower rate of positive CRM compared to laparoscopic 
TME (OR: 0.34, 95%CI: 0.12­0.93; I2 = 0%). A 
recent meta­analysis reinforced the previous results, 
demonstrating that TaTME attained significantly higher 
rate of complete and near complete mesorectal excision 
than laparoscopic TME[104]. Additionally, TaTME had 
wider CRM with a significantly lower number of patients 
with positive CRM (OR: 0.39, P = 0.02). However, more 
controlled trials including larger number of patients 
are required to validate the oncologic and pathologic 
outcomes with TaTME. 
Functional benefits: Bowel, bladder, and sexual 
dysfunctions are among the most common and 
devastating complications of rectal cancer surgery. 
TaTME decreases the number of permanent stomas, 
but at the cost of increasing the rate of coloanal 
anastomoses. With this, there is the theoretical risk 
of impaired continence and functional outcomes. Few 
studies have addressed long­term functional outcomes 
to date. Preliminary results demonstrate similar 
postoperative sphincter function when compared with 
laparoscopic or open TME[105­107]. A recent review of 30 
patients evaluating functional outcomes 6 mo after 
TaTME showed acceptable quality of life and functional 
outcomes, comparable to published results after 
conventional laparoscopic low anterior resection[108]. In 
this study, deterioration for all domains was observed 
at one month after surgery compared to baseline, but 
returned to baseline at 6 mo for all areas except social 
function and anal pain. More studies with larger sample 
sizes and longer follow up are needed. A lower rate of 
urinary dysfunction has been observed after TaTME, 
which can be attributable to the enhanced visualization 
that improves definition of anatomic landmarks 
and allows nerve­sparing dissection in the presacral 
plane[109]. 
The risk of urethral injury is a real concern, and a 
unique complication of the procedure; Studies have 
shown an incidence of more than 10%, in addition, 
injury of the urethral sphincter can lead to urinary 
Figure 3  Two-teams working simultaneously for transanal total 
mesorectal excision (“Cecil Approach”). Photo courtesy of Antonio Lacy, 
Hospital Clinic and AIS Channel.
Figure 4  Transanal access platform with trocar insertion in an inverted 
triangle shape. Photo courtesy of Antonio Lacy, Hospital Clinic and AIS Channel.
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incontinence and dysfunction[83]. The membranous 
urethra is put at risk if the posterior prostatic lobe 
is deflected downwards inadvertently, or during the 
perineal phase of an abdominoperineal resection. 
Urethral injury may be prevented with adequate 
training and mentoring of the technique and following 
a meticulous technique of dissection in the anterior 
plane[110]. Methods to better identify the urethra 
intraoperatively and reduce injury rates, such as with 
fluorescence imaging, have been described and may 
also be beneficial with this new technique[111,112].
Perioperative benefits 
Technical benefits of TaTME include having significantly 
shorter operation time than laparoscopic TME[103]. A 
plausible explanation is that the bottom­up approach 
overcomes the technical limitations associated with 
laparoscopic TME, enabling surgeons to proceed 
more easily and efficiently. Also, the simultaneous 
two­team technique can help reducing the operation 
time significantly[25]. Another technical advantage of 
TaTME is having lower rates of conversion to open 
surgery compared to laparoscopic TME (OR: 0.29, P = 
0.02)[104]. The overall conversion rate of laparoscopic 
TME was almost four­times that of TaTME (8.6% vs 
2.6%). On analysis of the reasons for conversion, 
technical difficulties accounted for 25% of conversions 
in the TaTME group vs 47% in the laparoscopic TME 
group. Technical difficulties necessitating conversion in 
the laparoscopic group were related to high BMI and 
narrow pelvis as previously implied. TaTME also allows 
for transanal specimen extraction, thus decreasing the 
need for an abdominal assist incision.
Safety: The safety and feasibility of TaTME for 
short and midterm outcomes has been extensively 
described[80,89,91,113­115]. A report from the TaTME 
International Registry reported postoperative morbidity, 
anastomotic leakage and mortality rates of 32.6%, 6.7% 
and 2.6%, respectively[83]. A pooled analysis in a recent 
systematic review had similar rates of intraoperative 
complications and lower rate of postoperative morbidity 
compared to laparoscopic TME, with no significant 
difference between the TaTME and laparoscopic TME 
in regards to anastomotic leak[104]. However, there 
remain some concerns about the rapid development 
of this new technique and critics would point to the 
more catastrophic complications including prostate 
and urethral injuries. But this had led to design and 
implementation of detailed national training programs 
which have been initiated in the United States and 
Europe. This may help safe expansion of the technique 
and mitigate the safety issues. 
Other side of the coin: Shortcomings of TaTME
Although TaTME has achieved promising oncological 
and functional results in treatment of rectal cancer as 
reported in several studies, the technique does have 
certain limitations that need to be addressed. Firstly, 
the bottom­to­up dissection approach followed in TaTME 
can be quite difficult since the majority of surgeons are 
not familiar with such different anatomical perspective 
for dissection, therefore adequate training under 
expert supervision is imperative before employing the 
technique in practice. Secondly, with new techniques 
new complications may arise, this is true with TaTME 
as a number of complications were recognized after 
the procedure. Complications specific to TaTME include 
formation of local collection or abscess secondary to 
bacterial contamination due to transection of the rectum 
at the start of the procedure. In one report[116], TaTME 
was found to be associated with positive cultures in 
more than one­third of the patient, with development of 
pre­sacral abscess in 17% of the patients.
As aforementioned, the risk of injury of the urethra 
and urethral sphincter, which can occur in up to 10% of 
patients, is a unique complication of TaTME compared to 
the abdominal approaches for rectal cancer[84]. The risk 
of urinary retention and transient urinary dysfunction 
was previously reported and minimal detrusor activity 
was documented in urodynamic studies implying 
neurogenic bladder dysfunction[82]. It is also worthy 
to note that the CO2 insufflation used to aid dissection 
might expose planes beyond the scope for dissection 
particularly during lateral and posterior dissection of the 
mid rectum which can lead to extending the dissection 
too deep into the pre­sacral space which carries a 
significant risk of injuring the autonomic nerves and 
venous plexus in this plane[96,117].
Figure 5  Transanal total mesorectal excision. A: Circumferential mucosal tattoo after pure-string placement; B: Bottom-up dissection; C: “Rendez-vouz” with the 
abdominal team. Photo courtesy of Antonio Lacy, Hospital Clinic and AIS Channel.
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TaTME: Research and education initiatives
In order to establish the efficacy of a new surgical 
treatment, well­designed controlled experiments must 
be performed. Trials such as the COLOR III[118] and the 
TaTME trial in United States are currently recruiting, 
with the primary outcome of non­inferiority for local 
recurrence. While we wait for the definitive outcomes 
from large­scale controlled trials, multicentre registries 
are valuable for quality assurance and audits to optimize 
and standardize outcomes. The international TaTME 
registry, in which worldwide surgeons performing TaTME 
are invited to join, is a secure online database funded 
by the Pelican Cancer Foundation (https://tatme.
medicaldata.eu). The analysis of this large population­
based cohort is a joint of effort with the objective of 
improving research and care of the patients with rectal 
cancer treated with TaTME.
In the last few years, there has been an increase in 
availability, quality, and utilization of online and social 
media resources for surgery. These platforms best 
feature offer instant and unlimited medical knowledge. 
Tools such as the online Advances in Surgery (AIS) 
Channel (https://aischannel.com) or iLappSurgery 
Foundation app (www.ilappsurgery.com) have gained 
favour in the surgical community. They have taken the 
next step by providing high­quality surgical education, 
which is clearly one of the keys to raise the standards 
of training. These two platforms are focused specifically 
on laparoscopic surgery and colorectal procedures, with 
TaTME being one of its cornerstones. 
All these initiatives for TaTME research, training and 
education have experienced a great acceptance. This 
is based on the obvious theoretical benefits that can 
overcome problems such as the risk for increased non­
complete specimens obtained by laparoscopy and the 
longer operative times and higher costs associated with 
robotics. The international TaTME registry, AIS Channel 
and iLappSurgery Foundation have been developed 
for being guidance not only for trainees but also for 
experienced surgeons. TaTME is a complex procedure 
to learn, so continuous quality improvement from 
data analysis as well as high­quality training programs 
are needed for correct standardization and safe 
implementation of the technique[98,100,101]. 
Future direction for TaTME
The survival outcomes with respect to disease re­
currence in rectal cancer surgery are directly related 
to the quality of resection[3], and thus the success of 
TaTME must be held against this quality assurance 
measure to ensure oncological parity and perhaps 
superiority. This new technique is complex and requires 
exceptional anatomical knowledge to perform an 
unfamiliar dissection. Previous laparoscopic colorectal 
experience and a high case volume are essential to 
reach a standard in an acceptable amount of time. 
Nursing/operating room staff and anaesthesiology also 
require specific training to become familiar with the 
new set up, particularly when performing a two­team 
approach, where the coordination among all operating 
room staff is crucial to avoid a potentially dangerous 
situation.
The learning curve of TaTME is yet to be established; 
however, according to estimation by expert groups 
approximately 20 consecutive cases are sufficient to 
develop an adequate learning curve for a surgeon 
proficient in laparoscopic and transanal surgery. In 
accordance with this appraisal, a minimum of five 
proctored cases is recommended in order to achieve 
an optimal level for the TaTME performance. However, 
establishing centres of excellence would allow surgeons 
to increase volume of cases and allow training of more 
junior surgeons in a safe manner. Different training 
courses taught by expert groups are available, which 
generally include didactic lessons, live cases, and 
hands­on cadaver labs. After completion of the courses, 
proctoring in the origin institutions should be the next 
step in the adoption process. Mentors should travel 
and proctor cases along with the trainees, to show 
on the spot the tips and tricks as well as adjusting 
the technique to the site´s intrinsic characteristics. 
Validation and accreditation of the technique are also 
under development and a matter of discussion in the 
international surgical societies[98,100].
CONCLUSION 
The TaTME was developed from existing platforms and 
as an attempt to resolve the challenges of minimally 
invasive low rectal cancer surgery. As evidence for 
safety and feasibility accumulates, and with the im­
plantation of structured training programs in order to 
standardize training, teaching, and safe expansion, 
TaTME seems on course for further uptake. The 
improved visibility of the pelvic structures and better 
accessibility for ultralow anastomoses may render the 
transanal approach ideal for a wide variety of cases. 
The indications for TaTME are currently expanding 
beyond mid and low rectal cancers, and open up new 
possibilities to use the approach for different diseases. 
Although the initial results of TaTME are promising and 
encouraging, further controlled clinical trials including 
larger number of patients with long­term follow­up 
are required to validate the oncologic and pathologic 
outcomes of TaTME. With the international registry and 
ongoing controlled trials, we look forward to long­term 
outcomes with this innovative approach.
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